Maxim Group Reiterates $5.00 Price Target for Cytori Therapeutics Inc (CYTX)
Cytori Therapeutics Inc (NASDAQ:CYTX) has been assigned a $5.00 price objective by investment analysts at Maxim Group in a research note issued on Thursday. The brokerage currently has a “buy” rating on the biotechnology company’s stock.
Several other brokerages have also recently issued reports on CYTX. Zacks Investment Research upgraded Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a research note on Tuesday, July 11th. B. Riley restated a “neutral” rating on shares of Cytori Therapeutics in a research note on Wednesday, August 16th. Finally, ValuEngine cut Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st.
Shares of Cytori Therapeutics (NASDAQ:CYTX) traded up 7.53% during trading on Thursday, reaching $0.50. The company’s stock had a trading volume of 3,050,513 shares. The firm’s 50-day moving average is $0.41 and its 200-day moving average is $0.76. The stock’s market capitalization is $17.36 million. Cytori Therapeutics has a 12-month low of $0.28 and a 12-month high of $2.13.
Cytori Therapeutics (NASDAQ:CYTX) last announced its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). Cytori Therapeutics had a negative return on equity of 202.62% and a negative net margin of 450.34%. The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $2.23 million. During the same quarter in the previous year, the business earned ($0.43) earnings per share. The company’s revenue for the quarter was down 18.2% compared to the same quarter last year. Equities analysts expect that Cytori Therapeutics will post ($0.60) earnings per share for the current year.
Hedge funds have recently made changes to their positions in the stock. Sabby Management LLC raised its position in Cytori Therapeutics by 28.0% during the second quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock valued at $1,789,000 after acquiring an additional 355,504 shares in the last quarter. Perkins Capital Management Inc. raised its position in Cytori Therapeutics by 99.0% during the second quarter. Perkins Capital Management Inc. now owns 874,896 shares of the biotechnology company’s stock valued at $962,000 after acquiring an additional 435,217 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Cytori Therapeutics by 81.9% in the second quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after buying an additional 275,653 shares in the last quarter. Institutional investors own 11.82% of the company’s stock.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.